Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,211
  • Shares Outstanding, K 4,562
  • Annual Sales, $ 63,910 K
  • Annual Income, $ -22,930 K
  • 60-Month Beta 1.01
  • Price/Sales 1.43
  • Price/Cash Flow N/A
  • Price/Book 0.70
Trade CDTX with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 57.81%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -5.22
  • Number of Estimates 1
  • High Estimate -5.22
  • Low Estimate -5.22
  • Prior Year -1.80
  • Growth Rate Est. (year over year) -190.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.77 +20.52%
on 08/08/24
13.37 -2.90%
on 07/30/24
+1.50 (+13.07%)
since 07/23/24
3-Month
10.45 +24.21%
on 06/24/24
14.54 -10.76%
on 06/12/24
+1.06 (+8.89%)
since 05/23/24
52-Week
10.00 +29.75%
on 04/23/24
24.40 -46.80%
on 04/03/24
-3.44 (-20.95%)
since 08/23/23

Most Recent Stories

More News
Cidara Therapeutics: Q2 Earnings Snapshot

Cidara Therapeutics: Q2 Earnings Snapshot

CDTX : 12.98 (-0.15%)
Cidara Therapeutics: Q1 Earnings Snapshot

Cidara Therapeutics: Q1 Earnings Snapshot

CDTX : 12.98 (-0.15%)
Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
META : 528.00 (-0.74%)
TSLA : 220.32 (+4.59%)
HAS : 68.02 (+1.80%)
TXN : 209.88 (+3.00%)
ODFL : 203.77 (+1.43%)
MSFT : 416.79 (+0.30%)
GOOGL : 165.62 (+1.11%)
MRK : 116.60 (+0.04%)
GILD : 76.72 (+1.08%)
CAT : 348.41 (+1.77%)
Cidara Therapeutics: Q3 Earnings Snapshot

Cidara Therapeutics: Q3 Earnings Snapshot

CDTX : 12.98 (-0.15%)
Cidara Therapeutics: Q2 Earnings Snapshot

Cidara Therapeutics: Q2 Earnings Snapshot

CDTX : 12.98 (-0.15%)
Cidara Therapeutics: Q1 Earnings Snapshot

Cidara Therapeutics: Q1 Earnings Snapshot

CDTX : 12.98 (-0.15%)
Cidara Therapeutics: Q4 Earnings Snapshot

Cidara Therapeutics: Q4 Earnings Snapshot

CDTX : 12.98 (-0.15%)
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYOâ„¢ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYOâ„¢ (rezafungin for injection) for the treatment...

CDTX : 12.98 (-0.15%)
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that...

CDTX : 12.98 (-0.15%)
Cidara Therapeutics: Q3 Earnings Snapshot

Cidara Therapeutics: Q3 Earnings Snapshot

CDTX : 12.98 (-0.15%)

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 13.51
2nd Resistance Point 13.25
1st Resistance Point 13.12
Last Price 12.98
1st Support Level 12.73
2nd Support Level 12.47
3rd Support Level 12.34

See More

52-Week High 24.40
Fibonacci 61.8% 18.90
Fibonacci 50% 17.20
Fibonacci 38.2% 15.50
Last Price 12.98
52-Week Low 10.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar